Insider Trading April 21, 2026 04:36 PM

Equitable Holdings CEO Disposes $1.65M in Shares, Exercises Options for 27,200 Shares

Mark Pearson executed a Rule 10b5-1 sale and concurrently exercised employee stock options; company fundamentals and merger developments also highlighted

By Sofia Navarro EQH
Equitable Holdings CEO Disposes $1.65M in Shares, Exercises Options for 27,200 Shares
EQH

Equitable Holdings CEO Mark Pearson sold 39,700 shares under a pre-established Rule 10b5-1 plan on April 20, 2026, for about $1.65 million and exercised options to acquire 27,200 shares at $23.18 each. The transactions leave Pearson with 789,183.2978 shares. The stock trades at $41 with an $11.5 billion market cap amid mixed financial signals including a Q4 2025 revenue shortfall and ongoing merger-related agreements.

Key Points

  • Mark Pearson sold 39,700 shares on April 20, 2026, under a Rule 10b5-1 plan adopted May 16, 2025, generating $1,652,639 in proceeds.
  • Pearson concurrently exercised options to acquire 27,200 shares at $23.18 each, representing $630,496; the options were granted under the 2019 Omnibus Incentive Plan and began vesting on February 26, 2021.
  • Equitable's recent financials show Q4 2025 EPS of $1.76 matching expectations but revenue of $3.28 billion, a 16.96% negative surprise versus estimates; merger-related agreements and analyst re-ratings are also in play.

Equitable Holdings President and Chief Executive Officer Mark Pearson completed a set of transactions on April 20, 2026, that combined an insider sale under a Rule 10b5-1 trading plan with the exercise of employee stock options.

Under the Rule 10b5-1 plan that Pearson adopted on May 16, 2025, he sold 39,700 shares of Equitable Holdings common stock (NYSE: EQH). The shares were disposed of at prices between $41.2200 and $42.0700 per share, producing a weighted average sale price of $41.6282 and resulting in proceeds of $1,652,639 - approximately $1.65 million.

At the same time, Pearson exercised employee stock options to obtain 27,200 shares of common stock at $23.18 per share. The exercise represented a cash value of $630,496. These options originated from the Issuer's 2019 Omnibus Incentive Plan and began vesting in three installments beginning February 26, 2021.

Following the sales and the option exercise, Pearson's direct holdings in Equitable Holdings total 789,183.2978 shares. That total includes Restricted Stock Units and 11,011 shares acquired through the Employee Stock Purchase Plan.

Equitable Holdings' shares are trading at $41, and the company carries an $11.5 billion market capitalization. Third-party valuation commentary cited in available analysis describes the stock as appearing overvalued at current levels. The firm has raised its dividend for eight consecutive years and currently yields 2.59%.

Analysts project earnings of $7.25 per share for 2026, and Equitable's next scheduled earnings report is due May 4. In the company's recently reported fourth-quarter 2025 results, reported earnings per share matched analyst expectations at $1.76. However, revenue fell short of projections, with reported revenue of $3.28 billion versus an expected $3.95 billion, a negative surprise of 16.96%.

On the corporate development front, Equitable Holdings has entered into a Voting and Support Agreement with Nippon Life Insurance Company and Corebridge Financial. That agreement relates to a previously announced merger transaction involving Equitable, Corebridge, and several newly formed subsidiaries. Under the terms reported, Nippon Life has agreed to vote its Corebridge common shares in favor of the merger at an upcoming special stockholder meeting.

Market research and broker commentary cited alongside the transaction provide a mixed view. Raymond James upgraded Equitable Holdings to Strong Buy from Market Perform, pointing to a favorable outlook tied to the merger with Corebridge Financial. Barclays analysts also described Equitable as an attractive way for investors to gain exposure to the life insurance sector, based on their review of insurers' cash flow projections and private credit exposure.

The structure of the trades - a Rule 10b5-1 sale combined with an option exercise - left Pearson with fewer newly acquired shares than were sold on the same day. The available data shows exact sale prices, option exercise price, plan adoption date, vesting schedule start, and the post-transaction holding total, but does not provide further commentary from the company or the executive beyond the transaction details.


Contextual note - The facts above are limited to the reported transactions, company financial results already disclosed, analyst projections and the described Voting and Support Agreement. No additional commentary from company spokespeople or further transactional detail was provided in the record summarized here.

Risks

  • Revenue shortfall in Q4 2025 - reported revenue of $3.28 billion missed expectations by 16.96%, indicating potential near-term operational or demand pressures in the insurance sector.
  • Valuation concerns - third-party analysis characterizes the stock as appearing overvalued at current levels, which could affect investor sentiment in the insurance and financials sectors.
  • Merger execution risk - the Voting and Support Agreement and planned merger with Corebridge and related entities hinge on shareholder approvals and integration steps that carry execution uncertainty.

More from Insider Trading

OrbiMed Expands Stake in Traws Pharma via Strategic Private Placement Apr 28, 2026 Rexford Industrial Realty General Counsel Completes $1.18 Million Stock Sale Apr 28, 2026 Bicara Therapeutics CMO Executes Rule 10b5-1 Trading Plan Involving Share Sales and Option Exercises Apr 28, 2026 Abbott Laboratories Director Daniel Starks Executes Substantial Open Market Share Purchase Apr 28, 2026 BlackRock President Robert Kapito Executes $9.2 Million Share Sale Apr 28, 2026